• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Genfit S.A. ADR (NQ: GNFT )

    3.410 -0.080 (-2.29%)
    Streaming Delayed Price Updated: 11:42 AM EDT, Apr 25, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 12,217
    Open 3.420
    Bid (Size) 3.400 (7)
    Ask (Size) 3.500 (12)
    Prev. Close 3.490
    Today's Range 3.400 - 3.559
    52wk Range 2.893 - 4.750
    Shares Outstanding 38,888,379
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Earnings Scheduled For April 4, 2024
    Companies Reporting Before The Bell • Conagra Brands (NYSE:CAG) is likely to report quarterly earnings at $0.65 per share on revenue of $3.01 billion. 
    Via Benzinga
    Why CymaBay Morphed From Dollar Stock To Biotech Rocket
    The company is working on the first treatment that could make a difference in the itching associated with a liver disease. 
    Via Investor's Business Daily

    Performance

    YTD
    -15.38%
    -15.38%
    1 Month
    -7.21%
    -7.21%
    3 Month
    -13.89%
    -13.89%
    6 Month
    +14.81%
    +14.81%
    1 Year
    -8.82%
    -8.82%

    More News

    Read More
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Why CymaBay, With 172% Growth This Year, Just Surged For A Second Day Running
    Via Investor's Business Daily
    Intercept Pharma Gets Double Upgrade: Analyst Says OCA Combo Therapy Can Extend PBC Business
    Via Benzinga
    Analyst Expectations for Genfit's Future
    Via Benzinga
    Genfit To Buy This Swiss Firm Expanding Its Portfolio in Liver Diseases
    Via Benzinga
    Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Class
    Via Benzinga
    Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patients
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Why Renalytix Are Trading Higher By Over 48%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Via InvestorPlace
    Former Wall Street Darling Intercept Restructures After FDA Rejects Its Liver Drug
    Via Investor's Business Daily
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur
    Via Benzinga
    Earnings Scheduled For April 13, 2023
    Via Benzinga
    The 7 Best Biotech Stocks to Buy for February 2023
    Via InvestorPlace
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Earnings Scheduled For September 28, 2022
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    US Stock Futures Rise After Recording Worst Sell-Off Since June 2020; PPI Data In Focus
    Via Benzinga
    BRP, Conformis And 3 Stocks To Watch Heading Into Wednesday
    Via Benzinga
    Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary
    Via Benzinga
    GENFIT Gets FDA Orphan Drug Status For Liver Disease Candidate
    Via Benzinga
    Analyzing Genfit's Short Interest
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.